anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Inclisiran sodium＋rosuvastatin 20mg group: Rosuvastatin was given 20mg daily for one year, and Inclisiran was given three times in total. After the first injection, 284mg(1.5ml solution) was injected subcutaneously, the second injection was 3 months after the first injection, and the third injection was in the ninth month.
Constructs that are at least partially constructed of allograft cancellous bone are disclosed, along with cartilage particles that may be used with the constructs for repairing articular cartilage defects. A multi-piece construct includes a base member, a cap member and at least one pin that secures the cap member to the base member. The base member may be constructed of mineralized cancellous bone, and is used to replace the subchondral bone removed when a surgeon cuts a bore in the area of an adjacent cartilage defect. The base member includes a blind bore and first and second through-going transverse bores in opposite sides of a wall of the base member. The cap member includes an upper section that has a thickness that is similar to that of a patient's surrounding articular cartilage layer and a stem depending from the upper section that is dimensioned to be received in and by the blind bore of the base member. The stem includes a transverse through-going bore, which may be aligned with the transverse through-going bores of the base member to receive the pin therein when the construct has been assembled. The cap member is at least partially formed of demineralized allograft cancellous bone, into which a mixture containing lyophilized, freeze-milled allograft cartilage particles may be infused for the repair of articular cartilage defects. The cartilage particles have a size within a range of from about 10 microns to about 210 microns.
A technique is disclosed for providing problem and solution information, such as that relating to a particular application or protocol, to medical diagnostic institutions and systems. The information is created and stored on machine readable media. A user may enter a problem query at a user interface at the diagnostic institution or system and search a database of information located at a centralized service facility. A list of solutions to the query is displayed at the diagnostic institution. The user may then select and display a desired solution from the user interface. The particular solution may include textual and exemplary image descriptions of the solution. Moreover, additional links may be provided to access other related sources of information. The information stored on the machine readable media may be easily updated by adding new case problems and associated solutions as well as new solutions to existing case problems.
<P>PROBLEM TO BE SOLVED: To provide a new and safe elastase activity inhibitor and cosmetic composition.  <P>SOLUTION: The elastase activity inhibitor and the cosmetic composition contain an extracted or pressed material of at least one kind of a plant of the family Orchidaceae selected from varieties of Epipactis papillosa Franch et Savat., Neottia nidus-avis (L.)L.C. Rich. var. manshurica Komar, Cephalanthera longibracteata Blume and Dacrylorhiza incarnata (L.) Soo. These components have excellent elastase activity inhibiting action and high safety and are usable as an elastase activity inhibitor and a cosmetic composition imparting the skin with luster and springiness and preventing the aging of the skin.  <P>COPYRIGHT: (C)2004,JPO
<P>PROBLEM TO BE SOLVED: To obtain an antibacterial composition for birds with high antimicrobial potency, to obtain an egg-laying-improving additive for birds capable of improving the egg-laying ability of raised chickens, and to obtain a feed additive for birds.  <P>SOLUTION: The antibacterial composition for birds contains 30 mg of cephradine as a β-lactam-based antibiotic and 1.5 g of rutin as a flavonoid. The egg-laying-improving additive for birds and the feed additive for birds contain this antibacterial composition, respectively. When administered to birds such as raised chickens, the above additives can enhance the activity of an antibiotic or antibacterial agent against resistant bacteria without affecting the birds' health, thus improving their egg-laying ability. As a result, the amount of an antibiotic or antibacterial agent used during raising birds can be reduced, thus reducing the opportunity for bacteria to acquire resistance to the antibiotic.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND AND PURPOSE: Thrombo-inflammation is a key feature of stroke pathophysiology and provides multiple candidate drug targets. Thrombin exerts coagulation-independent actions via protease-activated receptors (PAR), of which PAR1 has been implicated in stroke-associated neuroinflammation. The role of PAR4 in this context is less clear. This study examined if the selective PAR4 antagonist ML354 provides neuroprotection in experimental stroke and explored the underlying mechanisms.
EXPERIMENTAL APPROACH: Mouse primary cortical neurons were exposed to oxygen-glucose deprivation (OGD) and simulated reperfusion ± ML354. For comparison, functional Ca2+-imaging was performed upon acute stimulation with a PAR4 activating peptide or glutamate. Male mice underwent sham operation or transient middle cerebral artery occlusion (tMCAO), with ML354 or vehicle treatment beginning at recanalization. A subset of mice received a platelet-depleting antibody. Stroke size and functional outcomes were assessed. Abundance of target genes, proteins, and cell markers was determined in cultured cells and tissues by qPCR, immunoblotting, and immunofluorescence.
KEY RESULTS: Stroke up-regulated PAR4 expression in cortical neurons in vitro and in vivo. OGD augments spontaneous and PAR4-mediated neuronal activity; ML354 suppresses OGD-induced neuronal excitotoxicity and apoptosis. ML354 applied in vivo after tMCAO reduced infarct size, apoptotic markers, macrophage accumulation, and interleukin-1β expression. Platelet depletion did not affect infarct size in mice with tMCAO ± ML354.
CONCLUSIONS AND IMPLICATIONS: Selective PAR4 inhibition during reperfusion improves infarct size and neurological function after experimental stroke by blunting neuronal excitability, apoptosis, and local inflammation. PAR4 antagonists may provide additional neuroprotective benefits in patients with acute stroke beyond their canonical antiplatelet action.
BACKGROUND: Elevated extracellular matrix (ECM) accumulation is a major contributing factor to the pathogenesis of fibrotic diseases. Recent studies have indicated that N6-methyladenosine (m6A) RNA modification plays a pivotal role in modulating RNA stability and contribute to the initiation of various pathological conditions. Howbeit, the precise mechanism by which m6A influences ECM deposition remains unclear.
METHODS: In this study, we used hypertrophic scars (HTSs) as a paradigm to investigate ECM-related diseases. We focused on the role of ALKBH5-mediated m6A demethylation within the pathological progression of HTSs and examined its correlation with clinical stages. The effects of ALKBH5 ablation on ECM components were studied both in vivo and in vitro. Downstream targets of ALKBH5, along with their underlying mechanisms, were identified using integrated high-throughput analysis, RNA-binding protein immunoprecipitation and RNA pull-down assays. Furthermore, the therapeutic potential of exogenous ALKBH5 overexpression was evaluated in fibrotic scar models.
RESULTS: ALKBH5 was decreased in fibroblasts derived from HTS lesions and was negatively correlated with their clinical stages. Importantly, ablation of ALKBH5 promoted the expression of COL3A1, COL1A1, and ELN, leading to pathological deposition and reconstruction of the ECM both in vivo and in vitro. From a therapeutic perspective, the exogenous overexpression of ALKBH5 significantly inhibited abnormal collagen deposition in fibrotic scar models. As determined by integrated high-throughput analysis, key ECM components including COL3A1, COL1A1, and ELN are direct downstream targets of ALKBH5. By means of its mechanism, ALKBH5 inhibits the expression of COL3A1, COL1A1, and ELN by removing m6A from mRNAs, thereby decreasing their stability in a YTHDF1-dependent manner.
CONCLUSIONS: Our study identified ALKBH5 as an endogenous suppressor of pathological ECM deposition, contributing to the development of a reprogrammed m6A-targeted therapy for HTSs.
A computer implemented method (1000) of characterising a tooth by analysing at least one digital representation of said tooth in its clinical environment, comprising: a) determining a parameter indicative for the position of the tooth in a mouth; b) determining a limited set of parameters for describing the tooth in a clinical environment, comprising parameters indicative of a size and shape of the tooth, and parameters for describing adjacent papilla's. Computer implemented method (1100) for adding teeth to a database. Computer implemented method (1200) for determining a matching score between teeth. Computer implemented method (1300) of searching a database to find matching teeth. Computer implemented method for allowing a user to design or define a dental restoration, and producing a 3D file for producing the dental restoration. Computer program product for any of these computer implemented methods. A digital database.
A lathering, emolient, skin-cleansing composition contains by weight of the composition, 8 to 24% water-soluble anionic synthetic detergent, at least 3% liquid water-insoluble fatty acid ester and water.  Specified anionic synthetic detergents are the salts of higher acyl esters of isethionic acid, lauryl ether sulphates, sulphated polyethoxy higher alkyl mono-esters of succinic acid, and mono-esters formed between higher acyl polyethoxy derivatives and one of the carboxyl groups of sulphosuccinic acid, sodium lauryl sulphate, sodium alkyl benzene sulphonate, sodium secondary alkyl sulphates, and the sodium salts of acyl derivatives of taurine or methyl taurine.  Specified fatty acid esters include isopropyl myristate, methyl laurate, isopropyl stearate, isopropyl linoleate and stearyl oleate.  The composition may be in the form of a cream, lotion, paste or milk and may also contain a fatty acid solid at body temperature or another fatty or waxy substance with a melting point above 40 DEG  C., cetyl alcohol, a thickener, e.g. methyl cellulose, a non-ionic emulsifying agent and/or a lower alcohol.  Small amounts of ingredients customarily present in toilet soap bars, e.g. preservatives, antioxidants, perfumes, electrolytes, germicides and sequestrants for heavy metal ions found in the raw materials for the compositions, may also be present.  Compositions containing the synthetic detergent at the lower specified limit may also contain a lather improver, e.g. lauric diethanolamide, high monofatty glycerides or fatty ureides.  The pH of the composition may be adjusted by the addition of an alkali, e.g. sodium hydroxide.  The composition may be made by heating a mixture of fatty ingredients to 60-80 DEG  C., heating a mixture of non-fatty ingredients to 60-80 DEG  C., mixing together the heated mixtures with agitation and cooling.
INTRODUCTION: Physical activity (PA) is associated with higher quality of life and probably better prognosis among colorectal cancer (CRC) patients. This study focuses on determinants of PA among CRC patients from diagnosis until 5 yr postdiagnosis.
METHODS: Sociodemographic and disease-related factors of participants of two large CRC cohort studies were combined. Moderate-to-vigorous PA during sport and leisure time (MVPA-SL) was measured at diagnosis (T0) and 6, 12, 24, and 60 months (T6 to T60) postdiagnosis, using the SQUASH questionnaire. Mixed-effects models were performed to identify sociodemographic and disease-related determinants of MVPA-SL, separately for stage I-III colon (CC), stage I-III rectal cancer (RC), and stage IV CRC (T0 and T6 only). Associations were defined as consistently present when significant at ≥4 timepoints for the stage I-III subsets. MVPA-SL levels were compared with an age- and sex-matched sample of the general Dutch population.
RESULTS: In total, 2905 CC, 1459 RC and 436 stage IV CRC patients were included. Patients with higher fatigue scores, and women compared with men had consistently lower MVPA-SL levels over time, regardless of tumor type and stage. At T6, having a stoma was significantly associated with lower MVPA-SL among stage I-III RC patients. Systemic therapy and radiotherapy were not significantly associated with MVPA-SL changes at T6. Compared with the general population, MVPA-SL levels of CRC patients were lower at all timepoints, most notably at T6.
CONCLUSIONS: Female sex and higher fatigue scores were consistent determinants of lower MVPA-SL levels among all CRC patients, and MVPA-SL levels were lowest at 6 months postdiagnosis. Our results can inform the design of intervention studies aimed at improving PA, and guide healthcare professionals in optimizing individualized support.
Whole-genome duplication (WGD; i.e., polyploidy) and chromosomal rearrangement (i.e., genome shuffling) significantly influence genome structure and organization. Many polyploids show extensive genome shuffling relative to their pre-WGD ancestors. No reference genome is currently available for Platanaceae (Proteales), one of the sister groups to the core eudicots. Moreover, Platanus × acerifolia (London planetree; Platanaceae) is a widely used street tree. Given the pivotal phylogenetic position of Platanus and its 2-y flowering transition, understanding its flowering-time regulatory mechanism has significant evolutionary implications; however, the impact of Platanus genome evolution on flowering-time genes remains unknown. Here, we assembled a high-quality, chromosome-level reference genome for P. × acerifolia using a phylogeny-based subgenome phasing method. Comparative genomic analyses revealed that P. × acerifolia (2n = 42) is an ancient hexaploid with three subgenomes resulting from two sequential WGD events; Platanus does not seem to share any WGD with other Proteales or with core eudicots. Each P. × acerifolia subgenome is highly similar in structure and content to the reconstructed pre-WGD ancestral eudicot genome without chromosomal rearrangements. The P. × acerifolia genome exhibits karyotypic stasis and gene sub-/neo-functionalization and lacks subgenome dominance. The copy number of flowering-time genes in P. × acerifolia has undergone an expansion compared to other noncore eudicots, mainly via the WGD events. Sub-/neo-functionalization of duplicated genes provided the genetic basis underlying the unique flowering-time regulation in P. × acerifolia. The P. × acerifolia reference genome will greatly expand understanding of the evolution of genome organization, genetic diversity, and flowering-time regulation in angiosperms.
We conducted two studies to evaluate the construct validity, short term test-retest reliability, and sensitivity to mental fatigue of the Stroop task when used with older adults. In Study 1, 40 participants visited our lab on two separate days. On the first visit, they took five screening scales, and we measured their height and body mass. On the second visit, they completed the Stroop task twice with a 30-minute interval between assessments. In Study 2, 15 different participants took a 30-minute Flanker/Reverse Flanker task during the interval between the two administrations of the Stroop tasks and they gave subjective ratings of their mental fatigue on the Visual Analogue Scale (VAS) prior to taking either of the Stroop tasks. In Study 1, participants showed a ceiling effect on the Stroop accuracy measure, there was strong concurrent validity for the Stroop with significant score differences between the Stroop's congruent and incongruent conditions (p < .001), and there was excellent response time reliability (ICC = 0.926) on day two when participants took the Stroop twice within a 30-minute inter-test interval. However, there were significant test-retest performance differences with respect to cognitive inhibition (p < .001). In Study 2, mental fatigue from the Flanker/Reverse Flanker test resulted in a significantly worse second Stroop performance (p = .045). We concluded that the Stroop task demonstrated strong concurrent validity and response time reliability among older adults, but it showed sensitivity to mental fatigue, and repeated administrations within the short 30-minute test-retest interval revealed that the most important Stroop measure (cognitive inhibition) was unreliable. We discuss the implications of these findings.
Itraconazole reduced busulfan clearance by up to 25% in patients receiving itraconazole compared to patients who did not receive itraconazole. Higher busulfan exposure due to concomitant itraconazole could lead to toxic plasma levels in some patients. Fluconazole had no effect on the clearance of busulfan. Patients treated with concomitant cyclophosphamide and busulfan with phenytoin pretreatment have increased cyclophosphamide and busulfan clearance, which may lead to decreased concentrations of both cyclophosphamide and busulfan. However, busulfan clearance may be reduced in the presence of cyclophosphamide alone, presumably due to competition for glutathione.

Diazepam had no effect on the clearance of busulfan.

No information is available regarding the penetration of busulfan into brain or cerebrospinal fluid.
The men will run on a treadmill for 10 minutes until exhaustion. Blood will be drawn before, 5 minutes after and an hour after the test.
The drug being tested in this study is called sapanisertib (MLN0128). Sapanisertib is being tested to assess its safety and tolerability when administered alone or in combination with paclitaxel in people who have nonhematologic malignancies. Sapanisertib is also being tested to characterize its PK properties (how is processed by the body) when administered with a high-fat meal compared to on an empty stomach. This study will look at side effects and lab results in people who take sapanisertib with or without paclitaxel.

This open label study enrolled 61 patients. Participants receiving only sapanisertib will participate in a 6-day PK Run-In Period where sapanisertib 4 mg capsules are administered under fasted conditions on Days 1 and 4, and with a high-fat breakfast on Day 3. The main treatment period will begin within 14 days from Day 6 of the PK Run-In Period. In the main treatment period participants will receive sapanisertib 4 mg daily in a 28-day Cycle for up to 12 cycles. Participants in the treatment arm receiving sapanisertib and paclitaxel will not have a PK Run-In Period and will receive sapanisertib 6 mg daily on Days 2-4, 9-11, 16-18, and 23-25 in a 28-day Cycle for up to 12 cycles and paclitaxel 80 mg/m\^2 intravenously (IV) on Days 1, 8, and 15 in 28-day Cycle, for up to 12 cycles. The dose of sapanisertib may be modified based on safety and tolerability during each 28-day cycle in either treatment arm.

This multi-centre trial will be conducted in the United States. The overall time to participate in this study is up to 15 months. Participants in the sapanisertib only arm will make up to 32 visits to the clinic and participants in the sapanisertib and paclitaxel arm will make up to 26 visits to the clinic. All participants will make a final visit to the clinic 30 days after the last dose of study drug for a follow-up assessment.
PURPOSE:To obtain a composition for oral cavity containing a cyclohexylcarbonyl compound and salt thereof as active ingredient, having periodontal tissue protecting action, etc., excellent in stability and useful for periodontosis. CONSTITUTION:The aimed composition containing a compound expressed by the formula (R is hydroxy or substituted phenoxy) and salt thereof. As the compound expressed by the formula, a compound expressed by the formula (R is hydroxyl or 4-benzyloxycarbonylphenoxy) is preferably used. As the salt thereof, a salt of HCl, H2SO4, fumaric acid, etc., and sodium salt, potassium salt, etc., of carboxyl group (when R is OH) is used. The composition can be used as toothpaste, liquid dentifrice, pasta, etc. The compound expressed by the formula is contained at a weight ratio of normally 0.01-5.0% based on the composition.
NEW MATERIAL:A triterpene based compound expressed by formula I (R is formula II or III). USE:An antitumor agent. PREPARATION:MAGIRESOZO (a seaweed, scientifically named Laurencia obtusa and belonging to red algae) is extracted with a hydrophilic organic solvent, e.g. methanol, etc., and the resultant extract is adsorbed on an active adsorbent, e.g. silica gel, etc., and adsorbed components are partially eluted and removed with a nonpolar organic solvent, e.g. benzene, etc. The adsorbed components which are not eluted by the above-mentioned treatment are eluted with a polar organic solvent, e.g. methanol, etc., to give a neutral crude extract, which is then purified by chromatography, e.g. ordinary adsorption chromatography, partition chromatography, etc., and/or fractional crystallization method, etc., to afford the aimed compound expressed by formula I.
BACKGROUND AND OBJECTIVE: The aim of this study was to evaluate the prevalence and risk factors associated with perioperative venous thromboembolism (VTE) in patients undergoing major oncologic surgery using an epidural catheter (EC) for postoperative analgesia with mechanical prophylaxis and without chemoprophylaxis.
METHODS: Six hundred and twenty-six patients undergoing major oncologic surgery from 2009 to 2023 were evaluated. VTE was defined as deep vein thrombosis above the level of the knee. Lower extremity venous duplexes (LEVDs) were done preoperatively and postoperatively after the EC was removed. All patients received mechanical thromboprophylaxis, but not chemical prophylaxis, while the EC was in place. A generalized linear multivariable model was constructed to identify risk factors that predict pre and postoperative VTE.
RESULTS: 29/626 patients (4.6%) were found to have preoperative VTE. 16/626 (2.6%) were found to have a postoperative VTE when their preoperative LEVD was negative. In comparison to patients without preoperative VTE, those with VTE were more likely to be male, anticoagulated, and have a history of coronary artery disease. Patients in the postoperative VTE group were older, male, anticoagulated, and had a history of VTE. On multivariable analysis, previous history of VTE was the risk factor most strongly associated with both pre and postoperative VTE.
CONCLUSION: Oncologic patients undergoing elective abdominopelvic surgery with epidural analgesia should be screened in the perioperative setting with LEVD to identify VTE and possibly prevent PE.
The single-nucleotide polymorphism rs3197999 in the macrophage-stimulating protein 1 gene is a missense variant. Studies have indicated that macrophage-stimulating protein 1 mediates neuronal loss and synaptic plasticity damage, and overexpression of the macrophage-stimulating protein 1 gene leads to the excessive activation of microglial cells, thereby resulting in an elevation of cerebral glucose metabolism. Traditional diagnostic models may be disrupted by neuroinflammation, making it difficult to predict the pathological status of patients solely based on single-modal images. We hypothesize that the macrophage-stimulating protein 1 rs3197999 single-nucleotide polymorphism may lead to imbalances in glucose and oxygen metabolism, thereby influencing cognitive resilience and the progression of Alzheimer's disease. In this study, we found that among 121 patients with mild cognitive impairment, carriers of the macrophage-stimulating protein 1 rs3197999 risk allele showed a significant reduction in the coupling of glucose and oxygen metabolism in the dorsolateral prefrontal cortex region. However, the rs3197999 variant did not induce significant differences in glucose metabolism and neuronal activity signals. Furthermore, the rs3197999 risk allele correlated with a higher rate of increase in clinical dementia score, mediated by the coupling of glucose and oxygen metabolism.